IMRE'S PROSORBA COLUMN TTP CLINICAL TRIAL
This article was originally published in The Gray Sheet
Executive SummaryIMRE'S PROSORBA COLUMN TTP CLINICAL TRIAL is set to begin following FDA investigational device exemption approval, announced by the company Jan. 18. The device will be evaluated for the treatment of thrombotic thrombocytopenic purpura, an autoimmune disease marked by low platelet count, destruction of red blood cells and kidney failure or neurological disorders.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.